Omeza

Omeza is a private, pre-revenue biotech company targeting the large and underserved chronic wound care market with its proprietary Omega-3-based platform. Its lead candidate, OCM™, is a multimodal wound matrix designed to reduce biofilm, inflammation, and support tissue remodeling, aiming to prevent amputations and improve healing outcomes. The company is led by a lean executive team but is supported by a strategically experienced board with deep expertise in life sciences, commercialization, and government reimbursement. Omeza's success hinges on clinical validation, regulatory clearance, and achieving reimbursement for its novel therapeutic approach.

Proprietary topical wound matrix platform based on Omega-3 fatty acids and bioactive components designed to modulate inflammation, reduce biofilm, and support all phases of wound healing.

Omeza competes in the advanced wound care market, which includes large medtech companies (e.g., 3M, Smith & Nephew, ConvaTec) offering a range of dressings, biologics, and negative pressure devices, as well as smaller innovators focused on novel biomaterials and cellular therapies. OCM™ must differentiate itself through its unique Omega-3-based, multimodal mechanism of action.